Medical cannabis white paper released as Australia moves towards legalisation
MGC Pharmaceuticals has been collaborating with the University of Sydney Business School community engagement program in the production of a medical cannabis white paper.
The paper, titled Clinical Evidence for Medical Cannabis: Epilepsy, Cancer and Multiple Sclerosis examines existing evidence supporting the efficacy of medical cannabis.
This second collaboration between the two also examines medical cannabis applicability to relieve associated symptoms for a range of health related issues, including pain nausea and loss of appetite.
For medical cannabis to become a trusted treatment option among medical professionals and patients alike, there needs to be rigorous clinical evidence supporting efficacy,” said MGC co-founder and managing director Nativ Segev.
“We believe in the potential of medical cannabis more than most, but that belief needs to be proven in the lab under strict conditions.”
MGC has provided support and expertise developed in the Israeli medical cannabis industry to the University of Sydney during the study, giving insight into the broader industry.
Of course this is still an early stage company and its expertise is some way off morphing into profitability, so if considering MGC as an investment, seek professional financial advice.
MGC is also in further discussions with leading Australian institutions to provide support and expertise, as they “strive to increase our understanding of the benefits of medical cannabis and its potential uses as a safe and effective treatment option,” Segev concluded.
Co-ordinator of the study Michael Katz of the University of Sydney believes Australia has made great strides in medical cannabis advancement.
“Australia has made great advances in paving the way for medical cannabis to be available as a treatment option, but we now need to undertake more research to understand exactly how and why it can be used effectively with patients.”
Certainly governments are taking a broader view of the industry.
In July this year, the NSW government was given approval to grow cannabis under licence from the federal government as part of research into the best way to cultivate the plant.
According to the NSW state government, this move lays the foundations for private growers to supply medical marijuana.
“This underpins the potential pharmaceutical supply of cannabis-based medicines made in Australia,” said the NSW Primary Industries Minister, Niall Blair. “We are the first state to be authorised by the Commonwealth to conduct cultivation research.”
The move comes as medicinal cannabis will become legal, but strictly controlled from November this year, under a formal decision reached by the Therapeutic Goods Administration in early September.
Earlier in the year, the Federal Parliament lent bipartisan support to changes to the Narcotic Drugs Act to allow cannabis to be legally grown and produced in Australia for medicinal purposes as part of a national scheme.
NB: The new White Paper can be found here.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.